Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL

This is a Prospective Single Center, open label, Non-randomized, Single Arm, Single Dose, Phase II Clinical Trial. Adult patients \>18-year-old with CD19+ Non-Hodgkin lymphoma are eligible for the study if they meet eligibility criteria. Patients will receive a fresh single dose of MB-CART-19.1 and will be followed for 12 months and evaluated for efficacy and safety.

NCT Number	NCT07271121
Lead Sponsor	King Hussein Cancer Center
Conditions	Non-Hodgkin Lymphoma Refractory/ Relapsed
Enrollment	26 participants
Start Date	2025-02-12
Primary Completion	2028-03-30 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-09